Wells AU, Flaherty KR, Brown KK, et al. - Among patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis enrolled in the INBUILD trial, which was a randomised, double-blind, placebo-controlled, parallel group trial performed at 153 sites in 15 countries, nintedanib was compared with placebo in terms of efficacy and safety. Researchers intended to establish the impacts of nintedanib in subgroups based on ILD diagnosis (hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs). Random assignment 1:1 of the participants was done to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. The findings of the INBUILD trial, which was although not designed or powered to afford proof for an advantage of nintedanib in particular diagnostic subgroups, revealed that treatment with nintedanib led to a decrease in the rate of ILD progression, as measured by forced vital capacity reduction, among patients with a chronic fibrosing ILD and progressive phenotype, regardless of the underlying ILD diagnosis.